Cantor Fitzgerald reiterates Nyxoah stock rating on U.S. launch By Investing.com

Cantor Fitzgerald reiterated an Overweight rating and $11 price target on Nyxoah (NASDAQ: NYXH) while Stifel maintained a $12 Buy target; the stock trades at $3.08 near its 52-week low of $3.02. Nyxoah reported LTM revenue growth of 121.63% and is entering its first full year of U.S. commercialization; management expects ACCCESS study results in late June/early July 2026, which Cantor cites as a key 2027 expansion catalyst. Stifel anticipates a shift to quarterly guidance for 2026; repeat orders as early as Q1 2026 are highlighted as an early commercial success indicator.

Analysis

Nyxoah’s early U.S. commercialization creates a classic execution vs. evidence bifurcation: market moves will be driven as much by repeat-order cadence and implant center throughput as by eventual trial readouts. Expect topline momentum to show up as step-function improvements in monthly recurring revenue once a threshold of ~50–75 active implanting sites reaches routine scheduling — that’s the inflection that changes the multiple, not initial placements.

Second-order beneficiaries include ambulatory surgery centers, third-party distributor partners, and small-cap med-tech contract manufacturers with spare capacity; conversely, incumbent device makers that rely on scale economics could see margin pressure if smaller vendors win share via lower pricing or faster channel expansion. Payment and coding updates will likely lag adoption by 2–4 quarters, creating a window where volume growth does not immediately translate to sustainable margin improvement.

Primary risks are operational: slower-than-expected repeat orders, adverse event reports concentrated in a narrow patient subset, or a disappointing mid-term clinical readout that forces reimbursement resets. Those outcomes would compress valuation sharply in the near-term (weeks–months), while upside requires sustained commercial durability and payer acceptance over 12–24 months — a classical binary, asymmetric payoff where execution risk dominates near-term price action.

Key Decisions for Investors

• Initiate a small-sized long (1–2% of NAV) in NYXH as a staged position over 8–12 weeks to average execution risk; target 150%+ upside over 12–18 months if repeat-order cadence accelerates, and size a hard stop at 25–30% downside to limit capital at risk.
• If you prefer options, buy an 12–18 month call spread (debit) to cap downside while preserving upside exposure to a positive commercialization inflection; size to equal 1–1.5% of NAV and target a 2.5x–4x return if commercial metrics and trial signals align.
• Relative-value pair: go long NYXH and short a larger incumbent sleep-apnea device name (e.g., INSP) sized 1:0.5 to isolate share-gain execution; this reduces market beta and pays off if Nyxoah’s throughput/physician adoption outpaces established players over 6–12 months, with stop-loss on the short if incumbent reports stronger-than-expected pricing or reimbursement wins.
• Hedge or protect around binary milestones: ahead of any pivotal readout windows, reduce net exposure or buy short-dated puts (6–9 months) sized to cover 30–50% of the long position — this preserves upside while mitigating sharp downside from an adverse clinical or safety surprise.